PharmaBoardroom

Francisco González, CEO of ProMéxico, the Mexican investment agency, describes the strengths of Mexico’s research and industrial base, untapped…

The general manager of ALK Czech Republic and Slovakia on his strategy which led to success within the first one and a half years of ALK’s physical…

Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia…

Pfizer Switzerland’s Pamela Alexa discusses launching Xeljanz (tofacitinib), a treatment for adult patients with moderate to severe active…

Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas…

Philippe Richert, President of the newly created region Grand Est (Regions Alsace, Champagne-Ardenne and Lorraine) shares the significance of life…

Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its…

The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must…

Switzerland’s pharma industry is moving beyond staid conservatism and embracing risk in order to compete internationally and foster a new culture of…

Gilles Pacaud and Christophe Bourillon discuss the importance of life sciences to Rockwell Automation France, industry trends and how the company…

Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater…

Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional…